Donepezil in Alzheimer’s Disease: What to Expect after 3 Years of Treatment in a Routine Clinical Setting

Åsa K. Wallin,Niels Andreasen,Sture Eriksson,Stellan Batsman,Birgitta Näsman,Anne Ekdahl,Lena Kilander,Mikaela Grut,Marie Rydén,Anders Wallin,Mikael Jonsson,Hasse Olofsson,Elisabeth Londos,Carina Wattmo,Maria Eriksdotter Jönhagen,Lennart Minthon

Donepezil in Alzheimer’s Disease: What to Expect after 3 Years of Treatment in a Routine Clinical Setting

2007

Åsa K. Wallin
Niels Andreasen
Sture Eriksson
Stellan Batsman
Birgitta Näsman
Anne Ekdahl
Lena Kilander
Mikaela Grut
Marie Rydén
Anders Wallin
Mikael Jonsson
Hasse Olofsson
Elisabeth Londos
Carina Wattmo
Maria Eriksdotter Jönhagen
Lennart Minthon

Background/Aims: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer’s disease. The outcome of continuous long-term treatment in

Keywords:

Alzheimer's disease
Geriatrics
Disease
Mini–Mental State Examination
Donepezil
Dementia
Psychiatry
Cognitive disorder
Medicine
Neurology
Degenerative disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations